'Scratch and sniff' test could help top doctors spot Parkinson's, says Newcastle expert
Prof Nicola Pavese, a consultant neurologist at the Royal Victoria Infirmary and a clinical neuroscience professor at Newcastle University, heads up PPMI in this country and is encouraging people to sign up for an innovative "scratch and sniff" test to help support pioneering research.
The PPMI is sponsored and part-funded by the Parkinson's research foundation set up by Back to the Future actor Michael J Fox. Prof Pavese said the study could could bring better treatments a "step closer" for people with Parkinson's and their families.
READ MORE: Woman caught performing sex act in Gateshead doorway while children were present
READ MORE: Major power outage in North Shields leaves 1,600 properties without electricity
He said: "Many conditions, such as Covid-19 or a common cold, can cause loss of smell, however a prolonged loss of smell might be a risk factor for developing brain disease, such as Parkinson's. Not everyone with smell loss will go on to develop brain disease, however we need to learn more about this connection to find effective treatments.
'Everyone who gets involved in the study is helping us to move a step closer to finding treatments for a condition that can have a huge impact on patients and their families."
The test takes 15 minutes to complete - and people who are over 40 and do not have the disease can take part, as can those who have been diagnosed with it in the last seven years and those who may have a sleep condition called REM sleep behaviour disorder which can be an early sign of brain disease risk, especially in combination with having a reduced sense of smell.
The test is posted out to people if they are eligible. Those who are not, can still take part in a study that is online-based and involves answering questionnaires about lifestyle risk factors that could lead to Parkinson's or other degenerative neurological conditions.
For more information, contact the Newcastle Hospitals NHS Trust's PPMI team on 0191 208 1241 or email nuth.caruresearch@nhs.net.
Our ChronicleLive Daily newsletter is free. You can sign up to receive it here. It will keep you up to date with all the latest breaking news and top stories from the North East.
ChronicleLive has created a dedicated WhatsApp community for breaking news and our biggest stories. You can join this WhatsApp community here. It will keep you up-to-date with news as it breaks and our top stories of the day sent directly to your phone.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
2 minutes ago
- The Hill
COVID cases rising in 25 states, but nationwide activity ‘low': CDC
Infections of COVID-19 are growing or likely growing in half of the U.S. as of early July, the Centers for Disease Control and Prevention (CDC) estimates. Modeling from the agency shows the West Coast, Southeast and South are the primary region for increased cases, though it maintains that activity overall remains 'low' nationwide. The probability that the epidemic is growing is highest in California, Texas, Louisiana, Mississippi, Alabama, Florida, Kentucky and Ohio, among others. The agency's wastewater monitoring dashboard tells a similar story, with Florida and Alabama leading the country in viral activity levels. Its most recent data comes from the week leading up to July 5. COVID-19 infections part of summer spike The uptick is part of a predicted summer spike, which lasts from July to September as part of a twice-a-year pattern recently identified by the CDC. The second spike comes in winter, typically from December to February. 'Our analysis revealed biannual COVID-19 peaks in late summer and winter, a pattern that is expected to persist as long as the rapid evolution of SARS-CoV-2 and cyclical S1 diversity continues,' agency scientists wrote. A vast majority of the country has seen a 'minimal' percentage of patients diagnosed with COVID-19 at emergency department visits in the past week, CDC data shows. Some states did report a 'substantial' percentage change, including New Mexico, Georgia, Kentucky and Virginia.' 'Razor blade throat' COVID variant: What to know The data comes amid reports of a new COVID-19 variant internationally. NB.1.8.1., or 'Nimbus,' has been afflicting patients with 'razor blade throat.' The symptom has been identified by doctors in the United Kingdom, India and elsewhere, according to media outlets in those countries. Airport screening in the U.S. detected the new variant in travelers arriving from those regions to destinations in California, Washington state, Virginia and New York.
Yahoo
an hour ago
- Yahoo
The key to living longer could be tied to a surprising substance, study suggests
A new study suggests that psilocybin, also known as magic mushrooms, could extend lifespan. Researchers at the Emory University Department of Medicine in Atlanta, Georgia, discovered that psilocybin extended cellular lifespan and improved survival in aged mice. Psilocybin is the "naturally occurring psychedelic compound produced by hallucinogenic mushrooms," as defined in the study. Single Dose Of 'Magic Mushrooms' Provides 5 Years Of Depression Relief, Researchers Find Psilocybin has recently received attention due to "considerable clinical evidence" for its potential in treating various psychiatric and neurodegenerative conditions, the researchers noted. The study, published in the journal Nature, uncovered the first experimental evidence that treatment with psilocin – the "active metabolite" in psilocybin – increases longevity in aged mice. Read On The Fox News App This suggests that psilocybin may be a "potent geroprotective agent," the researchers wrote. Co-author Louise Hecker of Emory University said the data suggests psilocybin impacts "multiple hallmarks of aging." This includes reducing oxidative stress levels and preventing DNA damage, also known as preserving "telomere length." (Telomere are DNA-protein structures on the ends of chromosomes, which help to prevent cellular damage.) Parkinson's Patients Who Take 'Magic Mushrooms' See Key Benefits, Study Finds "Psilocybin appears to slow the 'wear and tear' that accompanies aging," Hecker said in an interview with Fox News Digital. "Mice and cells are healthier and live significantly longer." The treatment led to "a dramatic impact on cellular life extensions" and increased the survival of mice, even when administered later in life, the researcher noted. The mice also appeared healthier, growing back black hair that was once white. "Most of what we know about psilocybin is clinical outcomes and what it does in the brain," Hecker commented. "These studies shed light on the fact that psilocybin has potent impacts on the entire body." As these are the first studies showing the impact of psilocybin on aging, Hecker noted that there is still "much more to learn" about the drug's potential. "What are the optimal dosing protocols for humans? What is the optimal age for treatment initiation for optimal benefits?" Hecker questioned. "Is there an age, beyond which point, when treatment does not provide efficacy? Are there potential harms or adverse effects associated with long-term treatment? What are the mechanisms of its action? All these questions need to be rigorously tested." Additional studies are needed to answer these questions and confirm whether treatment impacts lifespan, Hecker noted. Gabe Charambides, founder of Odyssey – America's first legal psilocybin retreat, located in Oregon – said he considers these findings "compelling." "While most human psilocybin trials have focused on mental health outcomes — depression, anxiety, PTSD — this work highlights physiological shifts, including markers of cellular aging," he said in an interview with Fox News Digital. While Charambides' retreat doesn't test for any biological changes, he said that many guests report relief from physical ailments like chronic pain and migraines. "Those self-reports suggest the mind–body effects the study hints at may translate to humans as well," he told Fox News Digital. Click Here To Sign Up For Our Health Newsletter Administration of psilocybin should differ "sharply" from mice to humans in terms of screening, preparation and safeguards, Charambides noted. Individuals who benefit the most from psilocybin therapy include those who "feel stuck" after significant life events – like childhood trauma, divorce, career upheaval or bereavement – or people who aim to improve their mental health, he added. Ryan Moss, chief science officer at Filament Health, a clinical-stage natural psychedelic drug development company in Canada, has emphasized the importance of administering psychedelics in a safe setting. For more Health articles, visit "Psychedelic experiences can sometimes feature anxiety, hallucinations and paranoia," Moss previously told Fox News Digital. "Some patients using traditional psychedelics have reported experiencing adverse cardiovascular events during clinical trials." To mitigate these risks, Moss recommended that clinical trial participants receive thorough preparation and monitoring by trained professionals during article source: The key to living longer could be tied to a surprising substance, study suggests
Medscape
2 hours ago
- Medscape
New Data on Postoperative Delirium a ‘Call to Action'
Postoperative delirium following noncardiac surgery was linked to a 3.5-fold higher risk for death or major complications, but low-cost interventions focusing on avoiding patient disturbances can mitigate those negative outcomes, a new landmark study showed. An estimated one in 30 patients in the study experienced postoperative delirium, with high levels of variation in incidence rates among hospitals. Researchers said the findings are a 'call to action' to health providers to proactively manage the risks of postoperative delirium. 'This study is not just about identifying a problem, but it's also about giving people a sense of the scope of the problem. When you do that, it kind of energizes people to say okay, let's go out and see if we can do something about this,' principal investigator Laurent Glance, MD, professor and vice-chair for research in the Department of Anesthesiology at the University of Rochester School of Medicine (URMC), Rochester, New York, told Medscape Medical News . The study is the largest to date to examine the clinical implications of postoperative delirium on a national scale and was published online on July 8 in JAMA Network Open . Acute Brain Failure Postoperative delirium was once thought to be a minor and temporary complication. However, that has changed over the past decade. The American Geriatrics Society, which describes postoperative delirium as 'acute brain failure,' recommends the condition be treated as a medical emergency that requires rapid diagnosis and treatment. The cost of managing the condition runs roughly $26 billion to $42 billion in the US each year, and recent studies have linked postoperative delirium to the development of dementia in older adults. For this study, investigators used Medicare claims data from 2017 to 2020 of more than 5.5 million adults over the age of 65 years (mean age, 74.7; 57.2% women). Postoperative delirium was identified based on ICD-10 codes. Postoperative delirium was identified in 3.6% of cases. Patients with delirium were more likely to be male and have comorbidities, including cerebrovascular disease, heart failure, and dementia. Compared to patients without delirium, those with the condition were significantly more likely to experience death or major complications (adjusted odds ratio [aOR], 3.47), non-home discharges (aOR, 3.96) and 30-day mortality (aOR, 2.77; P < .001 for all). Findings were similar even after adjusting for hospital characteristics and excluded the patients admitted in 2020 during the height of the COVID-19 pandemic. 'Opportunity for Improvement' Investigators also found a nearly threefold variation in the rates of postoperative delirium among the 3169 hospitals included in the study. 'When you see that level of variation, what it tells you is that there is an opportunity for improvement,' Glance said. In fact, researchers noted that prior work found that postoperative delirium is preventable in up to 40% of cases. '[Postoperative delirium] is not something that's guaranteed because you're older or because you have multiple medical problems,' lead author Heather Lander, MD and assistant professor in the Department of Anesthesiology and Perioperative Medicine at URMC, Rochester, New York, told Medscape Medical News . 'This is something that we as a healthcare system can identify early,' she added. Variability among institutions could also be due to differences in coding accuracy and delirium screening, instead of reflecting true differences in hospital performance, the investigators wrote. Delirium Often Underreported The incidence of postoperative delirium reported in the study is markedly lower than previously reported rates of roughly 20% for noncardiac surgery patients. The researchers noted that incidence of postoperative delirium is known to be underreported in Medicare claims data. Postoperative delirium can be miscoded as other conditions for financial incentives or go undetected by clinicians, particularly for hypoactive delirium where patients may not show typical symptoms of restlessness or disorientation. Commenting on the finding for Medscape Medical News , Donna Fick, PhD, distinguished professor at Pennsylvania State University College of Nursing, University Park, Pennsylvania, noted that the miscoding of postoperative delirium might underrepresent affected patients in the study. 'When you use ICD-10 codes, claims or administrative data to examine this problem, you're dependent on clinicians coding the delirium, and we know that that's grossly under representative,' said Fick, who was not part of the study. Given the poor health outcomes identified and extrapolated onto a likely higher number of patients affected, this is a 'really important study' to represent delirium impacts on a national scale, Fick added. The authors also did a good job of controlling for important variables, including economic and social determinants of health as well as frailty and comorbidity, she said. Reducing Delirium Rates Investigators also found that patients undergoing surgery in hospitals with a higher rate of postoperative delirium had 1.5-fold higher odds of experiencing it compared to hospitals with lower rates. However, 'the inference from that finding has to be very carefully interpreted,' Esther Oh, MD, PhD, professor and associate director of the Johns Hopkins Memory and Alzheimer's Treatment Center, Baltimore, told Medscape Medical News. Some hospitals that are referral-based will take sicker patients compared to smaller hospitals, and those that have a delirium screening policy will find more delirium as a direct result, Oh noted. Both Oh and Fick supported several low-cost, nonpharmacologic interventions to reduce delirium risk that Glance and colleagues recommended in the study, including avoiding sleep disturbance, sensory support and enhanced screening for at-risk patients. 'It would be our hope eventually that postoperative delirium will be one of the quality metrics that will be used by CMS to evaluate hospital quality,' Glance said. In doing so, public reporting will enhance transparency, awareness and accountability of this issue and hospitals might up their efforts to reduce the rates of postoperative delirium, he added.
